SMCHD1 is a target for gene activation therapy to treat Prader-Willi syndrome
Science Advances · 2026
DOI: 10.1126/sciadv.aej5702 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Megan Iminitoff und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, VIC, Australia. Hauptthemen laut MEDLINE: Prader-Willi Syndrome, Chromosomal Proteins, Non-Histone, Genetic Therapy. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Health and Medical Research Council of Australia, Research Training Program, Foundation for Prader Willi Research USA.
Abstract (Originalsprache)
Prader-Willi syndrome (PWS) is a neurodevelopmental disorder caused by loss of expression from the active paternal allele at an imprinted cluster on chromosome 15. Current treatments address individual symptoms rather than the underlying cause of disease. Because all patients preserve a normal but epigenetically silenced maternal copy of these genes, activation of this copy offers a potential disease-modifying therapy. Here, we investigated the epigenetic regulator SMCHD1. First, we demonstrated that SMCHD1 represses the PWS locus in both mice and humans, supporting its relevance as a therapeutic target. Second, we found that SMCHD1 represses the entire PWS locus in neural lineages, extending its previously known role beyond only part of the cluster. Deleting Smchd1 after early development in vivo activated PWS genes in disease-relevant mouse tissues including hypothalamus and improved phenotypes in a PWS mouse model. Despite broader genome-wide binding, postearly development targeting of SMCHD1 appeared remarkably safe, supporting its potential for gene activation therapy for PWS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, VIC, Australia.
- Department of Medical Biology, University of Melbourne, Melbourne 3010, VIC, Australia.
- Institute of Human Genetics, Heidelberg University, Heidelberg, Germany.
- Department of Diabetes, Monash University, Clayton, VIC, Australia.
- Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia.
ORCID-Profile: Megan Iminitoff, Anna Le Fevre, Tamara Cameron, Hannah K Vanyai, Caleb Chew, Kelsey Breslin, Quentin Gouil, James M Murphy, Andrew Keniry, Marnie E Blewitt
Förderung
- National Health and Medical Research Council of Australia
- Research Training Program
- Foundation for Prader Willi Research USA
- Rebecca L. Cooper Medical Research Foundation
- Prader Willi Research Foundation Australia
- Pamela and Lorenzo Galli Trust
- Brian M Davis Charitable Trust
- NHMRC IRIISS and Victorian State Government Operational Infrastructure Support
Zitieren
APA
Iminitoff, M., Le Fevre, A., Cameron, T., Vanyai, H. K., Chew, C., Kinkel, S. A., Breslin, K., Theiß, S., Gouil, Q., Thomas, M., Murphy, J. M., Schaaf, C. P., Keniry, A., & Blewitt, M. E. (2026). SMCHD1 is a target for gene activation therapy to treat Prader-Willi syndrome. Science Advances. https://doi.org/10.1126/sciadv.aej5702
Vancouver
Iminitoff M, Le Fevre A, Cameron T, Vanyai HK, Chew C, Kinkel SA, et al. SMCHD1 is a target for gene activation therapy to treat Prader-Willi syndrome. Science Advances. 2026. doi:10.1126/sciadv.aej5702
BibTeX
@article{Iminitoff2026,
author = {Iminitoff, Megan and Le Fevre, Anna and Cameron, Tamara and Vanyai, Hannah K and Chew, Caleb and Kinkel, Sarah A and Breslin, Kelsey and Theiß, Susanne and Gouil, Quentin and Thomas, Merlin and Murphy, James M and Schaaf, Christian P and Keniry, Andrew and Blewitt, Marnie E},
title = {SMCHD1 is a target for gene activation therapy to treat Prader-Willi syndrome},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aej5702}
}
EUVIMED